Dare Bioscience, Inc. current report, 21 October 2024

Dare Bioscience, Inc. — Form 8-K Summary

Filing date: October 21, 2024. This current report announces a financing agreement; it does not report quarterly or annual operating results.

Business context and reporting period

Dare Bioscience entered into a purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC on October 21, 2024. The arrangement gives Dare the option to sell shares over time; it is not a completed $15 million financing. The filing provides no financial statements or operating-period results.

Key financial and financing terms

  • Lincoln Park committed to purchase up to $15.0 million of Dare common stock, subject to agreement terms, purchase limits, and other conditions. Dare may choose whether and when to request purchases.
  • The 24-month purchase period begins only after the resale registration statement is effective, the final prospectus is filed, and other commencement conditions are satisfied. Dare agreed to file the registration statement by December 5, 2024.
  • Regular purchases are generally limited to 30,000 shares per business day, potentially rising to 35,000 or 40,000 shares at specified stock-price thresholds of $5.00 and $7.50, respectively. A single regular purchase may not exceed $500,000. Purchase pricing is based on specified market-price measures; accelerated purchases are also permitted under contract limits.
  • Nasdaq’s exchange cap is 1,711,172 shares, equal to 19.99% of the 8,555,864 shares outstanding before the agreement, unless stockholder approval is obtained or the applicable average sale price is at least $3.59 per share. Issuances remain subject to Nasdaq rules.
  • Dare issued Lincoln Park 137,614 shares as consideration for its commitment. Dare may not sell shares if that would cause Lincoln Park to beneficially own more than 4.99% of outstanding shares.
  • Dare expects any proceeds to support working capital and general corporate purposes. Actual proceeds depend on whether Dare requests purchases and the prices and frequency of sales.

The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures; these financial values are not applicable to the transaction announcement or are not disclosed in this filing.

Material changes, outlook, and risks

  • The agreement creates a potential source of equity financing, with possible dilution from the commitment shares and any additional shares sold. The full $15.0 million is not assured.
  • Dare may terminate the agreement after commencement without cost or penalty. Sales are suspended during specified suspension events; the agreement automatically terminates in the event of bankruptcy proceedings by or against Dare.
  • While the agreement is in effect, Dare generally may not enter into variable-rate equity transactions, subject to limited exceptions, including its previously announced at-the-market offering. Lincoln Park agreed not to short or hedge Dare common stock during the agreement term.
  • The company cautioned that potential purchases are forward-looking and subject to conditions and risks, including development and regulatory risks, stock-price volatility, and continued Nasdaq listing.

Important facts for investors to verify

  • Whether and when the resale registration statement became effective and the facility’s commencement conditions were met.
  • Shares sold, prices received, net proceeds, and remaining facility capacity in subsequent filings.
  • Potential dilution relative to shares outstanding, including treatment of the 137,614 commitment shares and the Nasdaq exchange cap.
  • Whether the $3.59 pricing condition, stockholder approval, or other Nasdaq requirements affect further issuances.
  • Any suspension events, termination, or changes to Dare’s financing needs and liquidity disclosed in later reports.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.